Sitagliptin plus chemo for advanced pancreatic cancer
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests adding sitagliptin (a diabetes drug) to standard chemotherapy (gemcitabine and nab-paclitaxel) for people with pancreatic cancer that has spread or cannot be removed by surgery. The goal is to see if the combination works better than chemo alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have pancreatic ductal adenocarcinoma that is locally advanced or has spread to other parts of the body (metastatic)
- You have not had chemotherapy for advanced disease, though prior treatment after surgery is okay if it ended more than 6 months ago
- You are generally able to care for yourself (ECOG score 0 or 1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—atebimetinib (a new targeted therapy), gemcitabine, and nab-paclitaxel (two standard chemotherapy drugs)—as a first treatment for pancreatic cancer that has spread beyond the pancreas. The goal is to see if adding atebimetinib helps patients live longer and feel better.
This trial tests a new combination of treatments for pancreatic cancer that has spread. It adds a type of immunotherapy (called serplulimab) and targeted radiation (SBRT) to the usual chemotherapy, to see if it works better than chemotherapy alone in shrinking the cancer and helping you live longer.
This trial tests whether giving extra diabetes medication along with standard chemotherapy can help control blood sugar and improve outcomes in people with pancreatic cancer that has spread. It may help you manage diabetes better during treatment.
This trial tests whether adding the diabetes drug canagliflozin to a standard chemotherapy medicine (gemcitabine) can help treat advanced pancreatic cancer. The goal is to see if this combination can shrink tumors or improve survival.
This trial tests a new drug called IBI343 combined with standard chemotherapy for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This study tests a new combination of two drugs for advanced pancreatic cancer. It aims to see if adding an immunotherapy drug (which helps your immune system attack cancer) to standard chemotherapy can help control the cancer better.
Hear when a new PDAC - Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.